These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26454214)

  • 1. Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy.
    Zhang Z; Yu X; Wang Z; Wu P; Huang J
    Cancer Lett; 2015 Dec; 369(2):331-5. PubMed ID: 26454214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives.
    Ghiringhelli F; Apetoh L
    Biomed J; 2015; 38(2):111-6. PubMed ID: 25163503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.
    Vasaturo A; Verdoes M; de Vries J; Torensma R; Figdor CG
    Immunobiology; 2015 Feb; 220(2):243-8. PubMed ID: 25466585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing dendritic cells in cancer.
    Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
    Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline-induced cytotoxicity in the GL261 glioma model system.
    Tavener AM; Phelps MC; Daniels RL
    Mol Biol Rep; 2021 Jan; 48(1):1017-1023. PubMed ID: 33387196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens.
    Wijayahadi N; Haron MR; Stanslas J; Yusuf Z
    J Chemother; 2007 Dec; 19(6):716-23. PubMed ID: 18230556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of anthracyclines: moving towards more personalized medicine.
    Apetoh L; Mignot G; Panaretakis T; Kroemer G; Zitvogel L
    Trends Mol Med; 2008 Apr; 14(4):141-51. PubMed ID: 18353726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells.
    Jenei V; Burai S; Molnár T; Kardos B; Mácsik R; Tóth M; Debreceni Z; Bácsi A; Mázló A; Koncz G
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):53-66. PubMed ID: 36451019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
    Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system.
    Bottone AE; de Beer EL; Voest EE
    J Mol Cell Cardiol; 1997 Mar; 29(3):1001-8. PubMed ID: 9152861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and antiproliferative activity of a novel N-acyl derivative of doxorubicin].
    Shcherbakov VM; Devichenskiĭ VM; Vorontsov EA; Kuznetsov SL; Kriukov LN
    Bioorg Khim; 1999 Mar; 25(3):226-9. PubMed ID: 10382042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
    Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of the antitumor drug epirubicin (4'-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius.
    Madduri K; Kennedy J; Rivola G; Inventi-Solari A; Filippini S; Zanuso G; Colombo AL; Gewain KM; Occi JL; MacNeil DJ; Hutchinson CR
    Nat Biotechnol; 1998 Jan; 16(1):69-74. PubMed ID: 9447597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged exposure to doxorubicin after radiotherapy in glioblastoma.
    Sardi I
    Future Oncol; 2016 Mar; 12(5):581-3. PubMed ID: 26794842
    [No Abstract]   [Full Text] [Related]  

  • 18. 2,4-Dinitrophenol as an Uncoupler Augments the Anthracyclines Toxicity against Prostate Cancer Cells.
    Adamczuk G; Humeniuk E; Adamczuk K; Grabarska A; Dudka J
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.
    Yang H; Yamazaki T; Pietrocola F; Zhou H; Zitvogel L; Ma Y; Kroemer G
    Cancer Res; 2015 Sep; 75(18):3812-22. PubMed ID: 26208907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic activity of some glycoconjugates including saponins and anthracyclines.
    Ekholm FS; Berényi Á; Lagerquist L; Saloranta T; Zupkó I; Schneider G; Wölfling J; Leino R
    Carbohydr Res; 2012 Jul; 356():295-8. PubMed ID: 22520504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.